Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
US12291555B2 · kind B2 · utility
0Cited by
2References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 1, 2022 |
| Grant date | May 6, 2025 |
| Priority date | — |
| Expiry date | Nov 7, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.